Wire · opportunities
Remibrutinib Meets Primary End Point in Phase 3 REMODEL Trials for Relapsing Multiple Sclerosis
◆ Sectors
Health
◆ Source
◆ Verified
Fusion42 · 2 September 2026 · Fusion42 review
Novartis' oral BTK inhibitor remibrutinib met the primary endpoint in two global Phase 3 REMODEL trials for relapsing multiple sclerosis, significantly reducing relapse rates and MRI lesions compared with teriflunomide, with a favourable safety profile.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
You face a shift in MS treatment with remibrutinib proving oral efficacy on par with infused therapies while keeping safety higher. If your focus is RMS therapy, reposition to emphasise oral BTK inhibitors as they reshape treatment options.
◆ Coverage
1 source · 1 Sep 2026
◆ Related on Wire
◆ Topics
Healthmultiple-sclerosisbtk-inhibitornovartisclinical-trialsoral-therapy